CN111205359B - 一种拟穴青蟹抗菌肽Scyreprocin及其应用 - Google Patents
一种拟穴青蟹抗菌肽Scyreprocin及其应用 Download PDFInfo
- Publication number
- CN111205359B CN111205359B CN201811394517.8A CN201811394517A CN111205359B CN 111205359 B CN111205359 B CN 111205359B CN 201811394517 A CN201811394517 A CN 201811394517A CN 111205359 B CN111205359 B CN 111205359B
- Authority
- CN
- China
- Prior art keywords
- antibacterial peptide
- scyreproxcin
- antibacterial
- scyreplacin
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 48
- 241001672730 Scylla paramamosain Species 0.000 title description 7
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 108700026244 Open Reading Frames Proteins 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000000845 anti-microbial effect Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 37
- 241000282414 Homo sapiens Species 0.000 abstract description 7
- 239000003242 anti bacterial agent Substances 0.000 abstract description 7
- 230000001954 sterilising effect Effects 0.000 abstract description 7
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 5
- 210000004185 liver Anatomy 0.000 abstract description 5
- 210000004738 parenchymal cell Anatomy 0.000 abstract description 5
- 210000005229 liver cell Anatomy 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000001228 spectrum Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 231100001083 no cytotoxicity Toxicity 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 19
- 241000894006 Bacteria Species 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 241000228245 Aspergillus niger Species 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 238000012258 culturing Methods 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 239000008363 phosphate buffer Substances 0.000 description 9
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 8
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 8
- 201000007336 Cryptococcosis Diseases 0.000 description 8
- 241000221204 Cryptococcus neoformans Species 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 241000222122 Candida albicans Species 0.000 description 7
- 241000192041 Micrococcus Species 0.000 description 7
- 241000589614 Pseudomonas stutzeri Species 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 229940095731 candida albicans Drugs 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 241000233866 Fungi Species 0.000 description 6
- 239000006143 cell culture medium Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 238000007865 diluting Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- PXPDDNZJJKVTBG-UHFFFAOYSA-N 8-hydroxy-4,5,6,7-tetramethyl-4h-isochromene-1,3-dione Chemical compound CC1=C(C)C(C)=C2C(C)C(=O)OC(=O)C2=C1O PXPDDNZJJKVTBG-UHFFFAOYSA-N 0.000 description 4
- 241000672609 Escherichia coli BL21 Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 241000607598 Vibrio Species 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000222178 Candida tropicalis Species 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000035784 germination Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000012257 pre-denaturation Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 239000013535 sea water Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JTAGHJPZEDNHHA-UHFFFAOYSA-N 3-[[2-[2-(3,4-dimethoxyphenyl)ethylamino]-2-oxoethyl]amino]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(NCC(=O)NCCC=2C=C(OC)C(OC)=CC=2)=C1 JTAGHJPZEDNHHA-UHFFFAOYSA-N 0.000 description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 2
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 241000238097 Callinectes sapidus Species 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 108050004290 Cecropin Proteins 0.000 description 2
- 101800003223 Cecropin-A Proteins 0.000 description 2
- 241001288713 Escherichia coli MC1061 Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 108700022013 Insecta cecropin B Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241000238102 Scylla Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000607291 Vibrio fluvialis Species 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 108010092854 aspartyllysine Proteins 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- HCQPHKMLKXOJSR-IRCPFGJUSA-N cecropin-a Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(N)=O)[C@@H](C)CC)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCCN)C1=CC=CC=C1 HCQPHKMLKXOJSR-IRCPFGJUSA-N 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- LGFCAXJBAZESCF-ACZMJKKPSA-N Ala-Gln-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O LGFCAXJBAZESCF-ACZMJKKPSA-N 0.000 description 1
- NIZKGBJVCMRDKO-KWQFWETISA-N Ala-Gly-Tyr Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NIZKGBJVCMRDKO-KWQFWETISA-N 0.000 description 1
- XXAMCEGRCZQGEM-ZLUOBGJFSA-N Asp-Ser-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O XXAMCEGRCZQGEM-ZLUOBGJFSA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 101710178508 Defensin 3 Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- SXFPZRRVWSUYII-KBIXCLLPSA-N Gln-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N SXFPZRRVWSUYII-KBIXCLLPSA-N 0.000 description 1
- QOXDAWODGSIDDI-GUBZILKMSA-N Glu-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N QOXDAWODGSIDDI-GUBZILKMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- RBOOOLVEKJHUNA-CIUDSAMLSA-N His-Cys-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O RBOOOLVEKJHUNA-CIUDSAMLSA-N 0.000 description 1
- 101000972273 Homo sapiens Mucin-7 Proteins 0.000 description 1
- 241000256025 Hyalophora Species 0.000 description 1
- OUUCIIJSBIBCHB-ZPFDUUQYSA-N Ile-Leu-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O OUUCIIJSBIBCHB-ZPFDUUQYSA-N 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 241001506991 Komagataella phaffii GS115 Species 0.000 description 1
- NKKFVJRLCCUJNA-QWRGUYRKSA-N Lys-Gly-Lys Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN NKKFVJRLCCUJNA-QWRGUYRKSA-N 0.000 description 1
- IPSDPDAOSAEWCN-RHYQMDGZSA-N Lys-Met-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IPSDPDAOSAEWCN-RHYQMDGZSA-N 0.000 description 1
- SBQDRNOLGSYHQA-YUMQZZPRSA-N Lys-Ser-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SBQDRNOLGSYHQA-YUMQZZPRSA-N 0.000 description 1
- PLOUVAYOMTYJRG-JXUBOQSCSA-N Lys-Thr-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PLOUVAYOMTYJRG-JXUBOQSCSA-N 0.000 description 1
- GIKFNMZSGYAPEJ-HJGDQZAQSA-N Lys-Thr-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O GIKFNMZSGYAPEJ-HJGDQZAQSA-N 0.000 description 1
- 108060003100 Magainin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- WPTHAGXMYDRPFD-SRVKXCTJSA-N Met-Lys-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O WPTHAGXMYDRPFD-SRVKXCTJSA-N 0.000 description 1
- 102100022492 Mucin-7 Human genes 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 1
- WOIFYRZPIORBRY-AVGNSLFASA-N Pro-Lys-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O WOIFYRZPIORBRY-AVGNSLFASA-N 0.000 description 1
- SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101100029566 Rattus norvegicus Rabggta gene Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- ULVMNZOKDBHKKI-ACZMJKKPSA-N Ser-Gln-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ULVMNZOKDBHKKI-ACZMJKKPSA-N 0.000 description 1
- BPMRXBZYPGYPJN-WHFBIAKZSA-N Ser-Gly-Asn Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O BPMRXBZYPGYPJN-WHFBIAKZSA-N 0.000 description 1
- VLMIUSLQONKLDV-HEIBUPTGSA-N Ser-Thr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VLMIUSLQONKLDV-HEIBUPTGSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 101150088517 TCTA gene Proteins 0.000 description 1
- 108010070741 Tachypleus tridentatus tachyplesin peptide Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- AKFLVKKWVZMFOT-IHRRRGAJSA-N Tyr-Arg-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O AKFLVKKWVZMFOT-IHRRRGAJSA-N 0.000 description 1
- RMRFSFXLFWWAJZ-HJOGWXRNSA-N Tyr-Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 RMRFSFXLFWWAJZ-HJOGWXRNSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 108010010430 asparagine-proline-alanine Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004040 defense response to microbe Effects 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 108010044348 lysyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- -1 salt ions Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004763 spore germination Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 108010032153 thanatin Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
- A23V2250/55—Peptide, protein hydrolysate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Insects & Arthropods (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种拟穴青蟹抗菌肽Scyreprocin及其应用,其氨基酸序列包括如SEQ ID NO 01所示的序列,采用基因工程技术表达、纯化获得。本发明的抗菌肽的抗菌谱广、抗菌效果好、杀菌速率快,显示出极大的应用价值,在制备抗菌剂方面有良好的应用。本发明的抗菌肽对小鼠肝实质细胞AML12、人正常肝细胞L02等无细胞毒性,可安全用于药物治疗或者作为饲料组合物使用。
Description
技术领域
本发明属于甲壳动物基因工程技术领域,具体涉及一种拟穴青蟹抗菌肽Scyreprocin及其应用。
背景技术
为满足世界人口快速增长伴随对食品需求的增长,近年来畜禽、水产养殖业快速发展,大量抗生素被应用于产业以抵抗各类病原菌。抗生素的应用提高了饲料利用效率及产业经济效益,而抗生素的滥用也使病原微生物产生耐药性及二重感染,残留于养殖土壤及水体、畜禽水产产品中的抗生素使产品质量及安全性受到严重影响,威胁人类健康。因此,寻找高效、绿色抗生素替代品迫在眉睫,成为近年来的研究热点。安全高效、不产生抗药性、无残留和可体内降解的抗菌肽被认为是抗生素的理想替代品之一。
抗菌肽(antimicrobial peptide,AMP)又称宿主防御肽(host defense peptide,HDP),是由生物有机体产生具有抗菌活性或防御功能的小分子肽类物质,是动物体先天性免疫防御***的重要组成部分。1972年,瑞典科学家Boman等首先在果蝇中发现抗菌肽及其免疫功能。1981年Boman等首次从美国天蚕(Hyalophora cecropin)中成功地分离到两种抗菌肽——天蚕素(Cecropin)A和B。此后,人们在植物、昆虫、两栖类、水产类以及哺乳类动物甚至一些细菌中都发现了抗菌肽类物质。迄今为止,大约有2800多种抗菌肽被分离出来,各种脊椎动物中已发现100多种。经过20多年的研究,人们对抗菌肽结构、功能及作用机制有了较深的认识。
天然抗菌肽通常由12至100个氨基酸残残基组成,多具有强碱性、热稳定性及广谱抗菌等特点,不仅对细菌、部分真菌、原生动物、耐药性细菌具有杀灭作用,亦可选择性杀伤肿瘤细胞,抑制乙型肝炎病毒等的复制。迄今为止,研究者们发现抗菌肽可通过多种不同的作用机制发挥其活性功能,主要包括以下六个途径:①大多数抗菌肽(如天蚕素Cecropin,猪小肠分离得到的抗菌肽Cecp等)通过胞膜攻击作用破坏微生物或癌细胞质膜结构,引起内容物大量渗出,最终导致肿瘤细胞和微生物的死亡;②某些抗菌肽(如融合抗菌肽DP1,抗菌肽RGD tachyplesin等)通过诱导细胞凋亡以杀灭肿瘤细胞;③人唾液抗菌肽MUC7及抗菌肽Thanatin通过攻击微生物线粒体,抑制细胞呼吸作用发挥其杀菌功能;④对抗菌肽dermaseptinS4进行改造后获得新型抗菌肽PVS4(13)可穿过细胞膜直接作用于肿瘤细胞染色质发挥杀伤作用;⑤天蚕素B、B1和B3不仅使癌细胞膜发生穿孔,还可以进一步破坏细胞微管的正常功能进而引起细胞骨架的完整性,阻止纺锤丝形成和游戏***的过程,破坏细胞器,最终杀伤肿瘤细胞;⑥人源抗菌肽β2 defensin3通过抑制细菌蛋白质合成及细胞壁的形成,使细菌无法维持正常的形态、生长受阻,最终导致细菌细胞壁穿孔,内容物外泄,达到其杀菌的效果。
以上已发现的大多数抗菌肽不仅对细菌有较强的抑杀效果,随着研究的深入开展,抗菌肽对真菌、原虫、病毒及癌细胞的杀伤能力受到广泛的关注,其中CecropinA、Magainin、Nisin等抗菌肽已先后在医药、食品和农业上得到了应用。抗菌肽作为新型抗菌物质,具有抗菌谱广、生物活性稳定等特点,其物理吸附、破坏微生物膜作用机制不易产生耐药性使其成为强有力的抗生素替代品。随着对抗菌肽结构及其作用机理的不断深入研究,更多新型、高效、广谱且低毒的抗菌肽及其改造产品将会在临床医学、饲料添加剂和畜禽水产养殖领域具有良好的应用前景。
发明内容
本发明的目的在于提供一种拟穴青蟹抗菌肽Scyreprocin。
本发明的另一目的在于提供上述拟穴青蟹抗菌肽Scyreprocin的应用。
本发明的技术方案如下:
一种拟穴青蟹抗菌肽Scyreprocin,其氨基酸序列包括如SEQ ID NO 01所示的序列。其由84个氨基酸组成,来源于拟穴青蟹,是具有抗菌功能的多肽。该抗菌肽84个氨基酸中包含15个带正电荷的氨基酸残基和7个带负电荷的氨基酸残基,根据氨基酸残基电荷预测该抗菌肽等电点为9.61,在pH等于7.0时带有7个正电荷。该抗菌肽的亲水性平均系数为-0.968,具有较强的水溶性,是一种带有正电荷的阳离子抗菌肽。
在本发明的一个优选实施方案中,其开放阅读框的核苷酸序列包括如SEQ ID NO02所示的序列。
在本发明的一个优选实施方案中,其分子量为9107.258道尔顿,分子式为C396H636N106O127S4。
本发明的技术方案之二:
一种抗菌组合物,其有效成分包括上述拟穴青蟹抗菌肽Scyreprocin。
本发明的技术方案之三:
一种饲料组合物,其有效成分包括上述拟穴青蟹抗菌肽Scyreprocin。
本发明的技术方案之四:
一种防霉防腐组合物,其有效成分包括上述拟穴青蟹抗菌肽Scyreprocin。
本发明的技术方案之五:
上述拟穴青蟹抗菌肽Scyreprocin在制备抗菌组合物中的应用。
本发明的技术方案之六:
上述拟穴青蟹抗菌肽Scyreprocin在制备饲料组合物中的应用。
本发明的技术方案之七:
上述拟穴青蟹抗菌肽Scyreprocin在制备防霉防腐组合物中的应用。
本发明的有益效果是:
1、本发明的拟穴青蟹抗菌肽Scyreprocin对多种革兰氏阴性菌、革兰氏阳性菌、真菌及霉菌有显著的抗菌效果。其中,对河流弧菌的最小抑菌浓度为1-2μM,对重要致病菌施氏假单胞菌最小抑菌浓度为0.5-1μM、金黄色葡萄球菌最小抑菌浓度为<0.5μM;对多种革兰氏阴性菌、革兰氏阳性菌的最小杀菌浓度为2-4μM。此外,对重要临床致病菌白色链球菌的最小抑菌浓度为2-4μM,新型隐球菌的最小抑菌浓度为1-2μM且最小杀菌浓度为8-16μM;对黑曲霉的最小抑菌浓度为4-8μM。因此与许多已知的海洋动物抗菌肽比较,其抗菌谱广、抗菌效果好、杀菌速率快,显示出极大的应用价值,在制备抗菌剂方面有良好的应用。
2、本发明的拟穴青蟹抗菌肽Scyreprocin对小鼠肝实质细胞AML12、人正常肝细胞L02等无细胞毒性,可安全用于药物治疗或者作为饲料添加剂使用。
附图说明
图1为本发明实施例1中拟穴青蟹抗菌肽Scyreprocin的基因工程表达纯化图。在图1中,左图为菌株表达纯化、浓缩后获得的Scyreprocin蛋白SDS-PAGE电泳结果:M,蛋白Marker26616;1,诱导前菌株总蛋白;2,诱导24h后菌株总蛋白;3,菌株超声破碎细胞上清;4,纯化获得的Scyreprocin蛋白。右图为蛋白纯化峰图,箭头所指为Scyreprocin蛋白纯化峰。
图2为拟穴青蟹抗菌肽Scyreprocin抑制黑曲霉孢子萌发检测的实验图。
图3为拟穴青蟹抗菌肽Scyreprocin对新型隐球菌(左上)、白假丝酵母(左下)、施氏假单胞菌(右上)、溶壁微球菌(右下)的杀菌动力学曲线图。在图3中,横坐标为时间(min),纵坐标为存活菌落数相对于起始菌落数的百分比。
图4为MTS法检测拟穴青蟹抗菌肽Scyreprocin对非癌细胞系小鼠肝实质细胞(AML12)、人正常肝细胞(L02)增殖影响的实验图。
具体实施方式
以下通过具体实施方式对本发明的技术方案进行进一步的说明和描述。
下述实施例涉及的菌种有:大肠杆菌(Escherichia coli)、大肠杆菌BL21(Escherichia coli BL21)、金黄色葡萄球菌(Staphylococcus aureus)、河流弧菌(Vibriofluvialis)施氏假单胞菌(Pseudomonas stutzeri)、溶壁微球菌(Micrococcuslysoleikticus)、白假丝酵母菌(Candida albicans)、克鲁假丝酵母菌(Candida krusei)、热带假丝酵母菌(Candida tropicalis)、新型隐球菌(Cryptococcus neoformans)、黑曲霉(Aspergillus niger)等,均购自中国科学院微生物研究所菌种保藏中心。大肠杆菌MCl061(Escherichia coli MC1061)购自Gene Power公司,毕赤酵母(Pichiapastoris GS115)购自Invitrogen公司。
实施例1拟穴青蟹抗菌肽Scyreprocin的制备
所述拟穴青蟹抗菌肽Scyreprocin的开放阅读框序列为:
通过RACE技术获得并验证了Scyreprocin基因全长cDNA序列。Scyreprocin基因的开放阅读框为255bp(含终止密码子TAA),GenBank登录号:MH488960。
根据Scyreprocin基因的cDNA序列,设计基因特异性引物通过RACE技术进行重复验证(表1)。
表1 Scyreprocin序列扩增引物列表
通过RACE技术扩增青蟹Scyreprocin基因非编码序列(以5′UTR扩增为例):
以申请人前期制备的RACE cDNA为PCR模板,具体反应体系如下:
①Outer PCR反应:
反应程序如下所述:
1)95℃预变性3min;
2)95℃变性30s,60℃退火30s,72℃延伸2min,20个循环;
3)72℃延伸10min;
4)4℃停止。
将上述第一轮PCR产物稀释50-100倍,作为模板进行巢式PCR扩增,反应体系如下:
②Inner PCR反应:
混合均匀,进行PCR反应。反应程序如下所述:
1)95℃预变性5min;
2)95℃变性30s,60℃退火30s,72℃延伸2min,30个循环;
3)72℃延伸10min;
4)4℃停止。
Scyreprocin基因的3′UTR扩增方法同5′UTR扩增方法类似,所得扩增产物测序后拼接获得Scyreprocin基因cDNA全长,设计合适的引物,以拟穴青蟹cDNA为模板,对拼接获得的Scyreprocin基因全长进行验证,PCR反应体系如下:
混合均匀,进行PCR反应。反应程序如下所述:
1)95℃预变性5min;
2)95℃变性30s,55℃退火30s,72℃延伸1min,30个循环;
3)72℃延伸5min;
4)4℃停止。
所述Scyreprocin基因来源于拟穴青蟹,其氨基酸序列为:
Scyreprocin的分子式为C396H636N106O127S4,分子量为9107.258道尔顿。经SignalP4.1软件预测,Scyreprocin无信号肽序列,全长84个氨基酸中包含15个带正电荷的氨基酸残基和7个带负电荷的氨基酸残基,根据氨基酸残基电荷预测该抗菌肽等电点为9.61,在pH等于7.0时带有7个正电荷。该抗菌肽的亲水性平均系数为-0.968,具有较强的水溶性,是一种带有正电荷的阳离子抗菌肽。
采用基因工程表达技术方法即可获得纯度达85%以上的拟穴青蟹抗菌肽Scyreprocin。本实施例中拟穴青蟹抗菌肽Scyreprocin由本实验室通过基因工程技术表达纯化获得(结果如图1所示)。
实施例2拟穴青蟹抗菌肽Scyreprocin基因工程表达产物的获得
(a)从拟穴青蟹cDNA模板中克隆获得拟穴青蟹抗菌肽Scyreprocin开放阅读框序列,克隆重组到载体pET28a,通过碱基测序确定读码正确的重组载体,转入表达菌株大肠杆菌BL21(Escherichia coli BL21),获得可表达带融合His标签的拟穴青蟹抗菌肽Scyreprocin的重组表达菌株。
(b)挑取表达菌株单克隆于液体LB培养基中,于37℃下以180rpm摇瓶培养10-14h后,以1∶1000转接到含0.5%葡萄糖的液体LB培养基中继续培养至OD600=0.3,加入IPTG使其终浓度为0.5mM以诱导表达,于16℃以160rpm转速继续培养表达菌株,24h后离心收集菌体,用50mM磷酸盐缓冲液(pH8.0)以1∶10体积比重悬菌体。
(c)获得重悬拟穴青蟹抗菌肽Scyreprocin表达后菌体中加入PMSF以抑制蛋白酶活性,利用超声破碎仪破碎菌体,12000rpm高速离心30min以获得含有拟穴青蟹抗菌肽Scyreprocin的菌体裂解上清液。菌体裂解上清液经过0.22μm滤膜过滤除去杂质后,通过镍柱亲和层析方法获得融合His标签的拟穴青蟹抗菌肽Scyreprocin。
(d)获得的融合His标签拟穴青蟹抗菌肽Scyreprocin于透析液(50mM Tris-HCl,50mM NaCl,pH8.0)中透析16-18h,以去除蛋白纯化液中的咪唑;再转移到MilliQ中继续透析10-12h,以去除蛋白纯化液中的盐离子。
(e)将透析后的重组表达拟穴青蟹抗菌肽Scyreprocin通过超滤管进行超滤浓缩,并以Bradford法测定浓缩后蛋白浓度,获得的浓缩后拟穴青蟹抗菌肽Scyreprocin分装保存于-80℃待用。获得的纯蛋白通过变性凝胶电泳及质谱分析,确定表达产物为拟穴青蟹抗菌肽Scyreprocin。
实施例3拟穴青蟹抗菌肽最小抑菌浓度(MIC:minimum inhibitionconcentration)的测定
(a)将保种的大肠杆菌、大肠杆菌MC1061、施氏假单胞菌、嗜水汽假单胞菌、金黄色葡萄球菌、溶壁微球菌等在营养肉汤平板上划线,河流弧菌在2216E海水肉汤平板上划线,在相应培养最适温度倒置培养12-16h;白假丝酵母菌、毕赤酵母、克鲁假丝酵母菌、热带假丝酵母菌、新型隐球菌在YPG平板上划线,于28℃培养1-2周;黑曲霉孢子涂布于PDA平板上,于28℃倒置培养3-7d。从各平板上挑取菌落接种于相应培养基斜面上,细菌继续培养10-16h,真菌继续培养1-3d,霉菌继续培养3-7d后,用10mM磷酸盐缓冲液(pH7.4)冲洗斜面,细菌用MH液体培养基∶10mM磷酸缓冲液=2∶3的混合培养基调整稀释至OD600=0.003;弧菌用海水培养基调整稀释至OD600=0.0006;酵母用YPD液体培养基∶10mM磷酸缓冲液=2∶3的混合培养基调整稀释至OD600=0.00067;霉菌用PDA液体培养基∶10mM磷酸缓冲液=1∶1的混合培养基调整稀释孢子浓度至5×104个/mL(具体操作见实施例4);弧菌用海水培养基2216E调整稀释至OD600=0.0006。准备好的菌液须在20min内使用。
(b)将抗菌肽Scyreprocin经0.22μm滤膜过滤后,利用Bradford法测定蛋白浓度,倍比稀释蛋白浓度为0.5、1、2、4、8、16、32μM,4℃保存备用。
(c)在96孔细胞培养板上进行最小抑菌浓度检测实验,每种被测菌按照以下操作设置空白对照组、阴性对照组和待测样品实验组,每组设置3个平行样:
阴性对照组:加50μL灭菌超纯水和50μL菌悬液;
空白对照组:加50μL待测蛋白样品和50μL磷酸盐缓冲液;
样品实验组:加50μL待测蛋白样品和50μL菌悬液。
对于细菌,将培养板置于各菌种相对应的最适培养温度下,培养18-24h,观察结果;
对于真菌、弧菌和霉菌,将培养板置于28℃培养1-2d,观察结果。
将96孔细胞培养板待测实验组中肉眼观察未有菌生长的孔中培养液混匀后,吸取2μL接种于相应固体培养基平板上,置于各最适生长温度继续培养24-48h,观察MBC(minimum bactericidal concentration)结果。
拟穴青蟹抗菌肽Scyreprocin MIC、MBC观察结果如表2所示:
表2拟穴青蟹抗菌肽Scyreprocin抗菌活性测定
注:
MIC:最小抑菌浓度(μM),用a-b表示。a:肉眼可见菌体生长的最高蛋白浓度;b:肉眼未见菌体生长的最低蛋白浓度
MBC:最小杀菌浓度(μM),能够杀死99.9%菌体的最低蛋白浓度
实施例4拟穴青蟹抗菌肽Scyreprocin抑制黑曲霉孢子萌发的测定
(a)将保种的黑曲霉涂布于PDA平板上,于28℃倒置培养3-7d;
(b)从平板上挑取菌丝体接种于PDA斜面上,于28℃继续培养3-7d。用10mM磷酸盐缓冲液(pH7.4)冲洗斜面,用细胞筛(孔径=100nm)过滤除去菌丝,收集霉菌孢子。用PDA液体培养基∶10mM磷酸盐缓冲液=1∶1的混合培养基调整孢子浓度为5×104个/mL。
(c)将Scyreprocin蛋白表达产物经0.22μm滤膜过滤后,倍比稀释蛋白至0.5、1、2、4、8、16、32μM,置于冰上待用。
(d)在96孔细胞培养板上,如下设置阳性对照组、待测实验组,每组设置三个平行样:
阳性对照组:加50μL孢子悬液和50μL 10mM磷酸盐缓冲液。
待测实验组:加50μL孢子悬液和50μL待测蛋白样品。
将96孔细胞培养板置于28℃培养箱中培养24h,用光学显微镜观察黑曲霉孢子的萌发结果。如图2所示,结果表明:在4μM浓度下,拟穴青蟹抗菌肽Scyreprocin可显著抑制黑曲霉孢子的萌发。
实施例5拟穴青蟹抗菌肽Scyreprocin杀菌动力学曲线
本实施例选取一种革兰氏阴性菌(施氏假单胞菌)、一种革兰氏阳性菌(溶壁微球菌)及两种真菌(白假丝酵母、新型隐球菌)作为被测菌进行拟穴青蟹抗菌肽Scyreprocin杀菌动力学曲线的测定。
(a)将保种的施氏假单胞菌及溶壁微球菌涂布于营养肉汤平板上,将保种的白假丝酵母及新型隐球菌涂布于YPD平板上,在最适培养温度倒置培养。
(b)从平板上挑取菌落接种于斜面上继续培养,用10mM磷酸盐缓冲液(pH7.4)冲洗斜面,用MH液体培养基(或YPD液体培养基)∶10mM磷酸缓冲液=2∶3的混合培养基调整菌悬液浓度至OD600=3.3×104cfu/mL。
(c)将Scyreprocin蛋白表达产物经过0.22μm滤膜过滤后,倍比稀释蛋白至0.5、1、2、4、8、16、32μM,置于冰上待用。
(d)在96孔细胞培养板上,设置阳性对照组、待测实验组,每组设置三个平行样:
阳性对照组:加100μL菌悬液和100μL 10mM磷酸缓冲液。
待测实验组:加100μL菌悬液和100μL待测蛋白样品。
将96孔细胞培养板置于28℃培养箱中继续培养,于0、15、30、60、90、120、180、240min后取适量培养液稀释后涂布营养肉汤平板或YPD平板,平板于菌种最适温度继续培养至单克隆生长,计数每个平板上克隆数目,统计分析并作杀菌动力学曲线(如图3所示)。结果表明:2倍MBC浓度可在作用100min内杀死50%的新型隐球菌及白假丝酵母,在500min后杀菌指数达到100%;2倍MBC浓度的拟穴青蟹抗菌肽Scyreprocin与溶壁微球菌作用60min后,杀菌指数达到100%;2倍MBC浓度的拟穴青蟹抗菌肽Scyreprocin与施氏假单胞菌作用180min后,杀菌指数达到100%。
实施例6拟穴青蟹抗菌肽Scyreprocin对动物细胞系增殖的影响
本实施例选取人正常肝细胞L02、小鼠肝脏实质细胞AML12作为受试细胞株,进行拟穴青蟹Scyreprocin对不同细胞增殖影响的检测。
(a)将AML12细胞、L02细胞在对应细胞培养基中培养至细胞接合度80-90%后,用含EDTA的胰酶消化并用相应细胞培养基重悬,以相应细胞培养基调整细胞密度,在96孔细胞培养板中每孔接种2×105个细胞,置于37℃细胞培养箱在5%CO2条件下过夜培养。
(b)待每孔细胞生长到接合度约60-70%时,吸取细胞培养基,用相应细胞培养基倍比稀释Scyreprocin蛋白至0.5、1、2、4、8、16μM,以正常细胞培养基为对照,每组设置3个平行样。
将96孔细胞培养板放入37℃、5%CO2条件下继续培养48h后,每孔加入20μL MTS试剂,放入培养环境反应2h后,用酶标仪测定在波长为490nm时的吸光值。如图4所示,结果表明:拟穴青蟹抗菌肽Scyreprocin对小鼠肝脏实质细胞AML12、人正常肝细胞L02无抑制其生长的作用。
以上所述,仅为本发明的较佳实施例而已,故不能依此限定本发明实施的范围,即依本发明专利范围及说明书内容所作的等效变化与修饰,皆应仍属本发明涵盖的范围内。
序列表
<110> 厦门大学
<120> 一种拟穴青蟹抗菌肽Scyreprocin及其应用
<160> 14
<170> SIPOSequenceListing 1.0
<210> 1
<211> 84
<212> PRT
<213> 拟穴青蟹(Scylla paramamosain)
<400> 1
Met Lys Glu Asp Ser Asn Ile Leu Asp Lys Thr Ala Lys Met Thr Lys
1 5 10 15
Gln Asn Lys Ala Leu Leu Phe Thr Ala Gly Gly Ala Ala Ala Phe Met
20 25 30
Ala Gly Tyr Tyr Tyr Tyr His Cys Asn Tyr Arg Asn Pro Ala Pro Lys
35 40 45
Lys Ser Gly Ser Thr Thr Ser Gln Asp Lys Thr Asp Ala Gln Ala Val
50 55 60
Gln Ser Ile Pro Ser Pro Ser Gly Asn Lys Gly Lys Glu Ser Lys Asp
65 70 75 80
Pro Lys Val Lys
<210> 2
<211> 255
<212> DNA
<213> 拟穴青蟹(Scylla paramamosain)
<400> 2
atgaaggaag acagcaacat tctagacaag accgccaaga tgaccaaaca gaacaaggcc 60
ctgctcttca ctgcaggcgg cgccgcggcg ttcatggcag gatactacta ctatcactgc 120
aattacagaa atcctgcacc caagaaaagt ggcagtacta cttcacaaga caagactgat 180
gctcaggcgg ttcagtctat cccctcaccc agtggcaaca agggcaaaga aagcaaggac 240
ccaaaagtaa aataa 255
<210> 3
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
gcaaagaaag caaggaccca aaa 23
<210> 4
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 4
tgctcaggcg gttcagtcta tcc 23
<210> 5
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 5
acaagaccgc caagatgacc aaa 23
<210> 6
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 6
tctgtttggt catcttggcg gtctt 25
<210> 7
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 7
ccactgggtg aggggataga ctgaa 25
<210> 8
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 8
acttttgggt ccttgctttc tttgc 25
<210> 9
<211> 24
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 9
ttcacgccac tcagtacaaa tcta 24
<210> 10
<211> 24
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 10
caaacataag taaagctgaa ggta 24
<210> 11
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 11
catggctaca tgctgacagc cta 23
<210> 12
<211> 34
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 12
cgcggatcca cagcctactg atgatcagtc gatg 34
<210> 13
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 13
taccgtcgtt ccactagtga ttt 23
<210> 14
<211> 32
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 14
cgcggatcct ccactagtga tttcactata gg 32
Claims (9)
1.一种拟穴青蟹抗菌肽Scyreprocin,其特征在于:其氨基酸序列如SEQ ID NO 01所示。
2.如权利要求1所述的一种拟穴青蟹抗菌肽Scyreprocin,其特征在于:其开放阅读框的核苷酸序列如SEQ ID NO 02所示。
3.如权利要求1所述的一种拟穴青蟹抗菌肽Scyreprocin,其特征在于:其分子量为9107.258道尔顿。
4.一种抗菌组合物,其特征在于:其有效成分包括权利要求1至3中任一权利要求所述的拟穴青蟹抗菌肽Scyreprocin。
5.一种饲料组合物,其特征在于:其有效成分包括权利要求1至3中任一权利要求所述的拟穴青蟹抗菌肽Scyreprocin。
6.一种防霉防腐组合物,其特征在于:其有效成分包括权利要求1至3中任一权利要求所述的拟穴青蟹抗菌肽Scyreprocin。
7.权利要求1至3中任一权利要求所述的拟穴青蟹抗菌肽Scyreprocin在制备抗菌组合物中的应用。
8.权利要求1至3中任一权利要求所述的拟穴青蟹抗菌肽Scyreprocin在制备饲料组合物中的应用。
9.权利要求1至3中任一权利要求所述的拟穴青蟹抗菌肽Scyreprocin在制备防霉防腐剂中的应用。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811394517.8A CN111205359B (zh) | 2018-11-21 | 2018-11-21 | 一种拟穴青蟹抗菌肽Scyreprocin及其应用 |
PCT/CN2019/103237 WO2020103511A1 (zh) | 2018-11-21 | 2019-08-29 | 一种拟穴青蟹抗菌肽Scyreprocin及其应用 |
US17/230,243 US11512120B2 (en) | 2018-11-21 | 2021-04-14 | Antimicrobial peptide Scyreprocin of Scylla paramamosain and method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811394517.8A CN111205359B (zh) | 2018-11-21 | 2018-11-21 | 一种拟穴青蟹抗菌肽Scyreprocin及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111205359A CN111205359A (zh) | 2020-05-29 |
CN111205359B true CN111205359B (zh) | 2021-08-20 |
Family
ID=70773651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811394517.8A Active CN111205359B (zh) | 2018-11-21 | 2018-11-21 | 一种拟穴青蟹抗菌肽Scyreprocin及其应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11512120B2 (zh) |
CN (1) | CN111205359B (zh) |
WO (1) | WO2020103511A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112955460B (zh) * | 2019-12-31 | 2022-05-10 | 厦门大学 | 一种拟穴青蟹抗菌肽Scyreprocin及其应用 |
CN114014923B (zh) * | 2020-10-27 | 2022-11-01 | 厦门大学 | 拟穴青蟹抗菌多肽Sp-LECin及其应用 |
CN114716512B (zh) * | 2021-06-28 | 2022-12-16 | 厦门大学 | 一种青蟹广谱抗菌肽Scyampcin44-63及其应用 |
CN114014910B (zh) * | 2021-11-18 | 2022-12-09 | 厦门大学 | 一种拟穴青蟹抗真菌多肽Spamptin72-91及其应用 |
CN114773436B (zh) * | 2022-04-27 | 2023-01-03 | 厦门大学 | 一种拟穴青蟹抗菌多肽SpRR20及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009019632A1 (en) * | 2007-08-06 | 2009-02-12 | Nxp B.V. | Signal processor comprising an integrating analog-to-digital converter |
CN102167736A (zh) * | 2011-05-17 | 2011-08-31 | 厦门大学 | 一种拟穴青蟹抗菌肽Sphistin及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103789317A (zh) * | 2014-01-08 | 2014-05-14 | 广西壮族自治区海洋研究所 | 拟穴青蟹抗菌肽hyastatin基因克隆及编码蛋白重组和用途 |
CN104151414B (zh) * | 2014-08-20 | 2017-06-20 | 厦门大学 | 拟穴青蟹抗菌肽SpHyastatin的制备方法与应用 |
CN105274134A (zh) * | 2015-11-25 | 2016-01-27 | 厦门大学 | 拟穴青蟹抗菌肽scy2的制备方法与应用 |
-
2018
- 2018-11-21 CN CN201811394517.8A patent/CN111205359B/zh active Active
-
2019
- 2019-08-29 WO PCT/CN2019/103237 patent/WO2020103511A1/zh active Application Filing
-
2021
- 2021-04-14 US US17/230,243 patent/US11512120B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009019632A1 (en) * | 2007-08-06 | 2009-02-12 | Nxp B.V. | Signal processor comprising an integrating analog-to-digital converter |
CN102167736A (zh) * | 2011-05-17 | 2011-08-31 | 厦门大学 | 一种拟穴青蟹抗菌肽Sphistin及其应用 |
Non-Patent Citations (2)
Title |
---|
A new antimicrobial peptide SCY2 identified in Scylla Paramamosain exerting a potential role of reproductive immunity;Kun Qiao,et al;《Fish Shellfish Immunol.》;20160218;第51卷;第251至262页 * |
拟穴青蟹抗菌肽SCY2在毕赤酵母中的表达及其抗菌活性;彭会 等;《大连海洋大学学报》;20180425;第33卷(第2期);第151至157页 * |
Also Published As
Publication number | Publication date |
---|---|
US20210317172A1 (en) | 2021-10-14 |
WO2020103511A1 (zh) | 2020-05-28 |
US11512120B2 (en) | 2022-11-29 |
CN111205359A (zh) | 2020-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111205359B (zh) | 一种拟穴青蟹抗菌肽Scyreprocin及其应用 | |
US11254717B2 (en) | Antimicrobial peptide Sparamosin from Scylla paramamosain and application thereof | |
CN110922457B (zh) | 禾谷镰刀菌分泌的植物免疫诱抗蛋白FgPII1及其应用 | |
CN110643612A (zh) | 一种卵形鲳鲹抗菌肽NK-lysin基因及应用 | |
Yin et al. | A specific antimicrobial protein CAP-1 from Pseudomonas sp. isolated from the jellyfish Cyanea capillata | |
CN102304516A (zh) | 拟穴青蟹阴离子抗菌肽的毕赤酵母表达产物及其制备方法 | |
CN111574610A (zh) | 大黄鱼抗菌肽piscidin 5-like type 4及其制备方法与应用 | |
CN109134635B (zh) | 一种具有复合生物活性的抗菌肽及其制备方法与应用 | |
CN113201059B (zh) | 一种桃蛀螟活性抗菌肽及其基因、重组载体和应用 | |
CN112321697B (zh) | 一种黑水虻抗菌肽Cecropin-α及其应用 | |
CN104356222B (zh) | 一种猪源抗菌肽pr‑39突变体及其制备方法和应用 | |
Ma et al. | Two Novel Duck Antibacterial Peptides, Avian $\beta $-Defensins 9 and 10, with Antimicrobial Activity | |
CN117384267A (zh) | 一种脊尾白虾抗菌肽、编码基因EcCrustin、重组菌及其应用 | |
CN116143882B (zh) | 一种三斑海马hepcidin抗菌肽及其应用 | |
CN107245491B (zh) | 来源于卷曲乳杆菌的iii型细菌素及其制备方法和用途 | |
CN109251936B (zh) | 一种光滑鳖甲丝氨酸蛋白酶抑制剂融合蛋白及制备与应用 | |
CN111748025B (zh) | 一种褐鲳鲉抗菌肽leap2及其应用 | |
CN110003318B (zh) | 褐鲳鲉抗菌肽moronecidin及其应用 | |
RU2618850C2 (ru) | Плазмидный вектор pET-mChBac75Na, штамм бактерии Eschrichia coli BL21(DE3/ pET-mChBac75Na для экспрессии антимикробного пептида минибактенецина ChBac7.5 Nα и способ получения указанного пептида | |
CN104878027A (zh) | 漾濞大泡核桃核糖核酸酶基因JsRNase及应用 | |
CN104109198B (zh) | 蛙皮抗菌肽ar‑23改构的衍生多肽与应用 | |
CN110128519B (zh) | 一种重组荞麦防御素蛋白及其制备方法和应用 | |
RU2456345C1 (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pЕ-Trx-Lc-def, ШТАММ Escherichia coli ДЛЯ ЭКСПРЕССИИ АНТИМИКРОБНОГО ПЕПТИДА ДЕФЕНСИНА ЧЕЧЕВИЦЫ Lens culinaris И СПОСОБ ПОЛУЧЕНИЯ УКАЗАННОГО ПЕПТИДА | |
CN107980802B (zh) | 环糊精葡萄糖基转移酶用于抑制棉花黄萎病菌的应用及抑菌剂 | |
CN102796744A (zh) | 一种番茄抗病毒蛋白基因的克隆 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |